Biorestorative Therapies, Inc. BRTX

2.55 0.04 1.59% as of 25 Sep
Market cap
$3.5M
P/E
0.0×
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S ratio
37.36 18.27 3.24 0.05 7.06 5.60 4.11 2.49 1.38 1.48
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/Operating CF
(1.28) (1.09) (0.23) 0.00 (0.95) (0.23) (0.30) (0.23) (0.24) (0.22)
P/B ratio
0.00 0.00 0.00 0.00 0.00 0.01 0.03 0.04 0.07 1.55
Price to Tangible BV
0.00 0.00 0.00 0.00 0.00 0.01 0.03 0.04 0.07 0.00
EV/Sales
44.67 15.09 6.90 1.24 22.72 (447.35) (117.65) (73.12) (25.27) (6.62)
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.82 0.75 0.71 0.89 0.15
EV/Operating CF
(0.32) (0.32) (0.15) (0.02) (0.89) 6.18 2.38 1.66 1.23 0.22
EV/FCF
(0.31) (0.31) (0.15) (0.02) (0.87) 6.06 1.92 1.37 1.06 0.20
Quick Ratio
0.01 0.06 0.02 0.00 2.95 57.81 33.53 4.25 2.91 0.80
Current Ratio
0.01 0.06 0.02 0.01 3.05 59.01 34.36 4.37 2.97 0.84
Net Debt/EBITDA
(0.04) 0.03 (0.08) (0.11) (0.89) 0.83 0.77 0.74 0.94 0.19
Debt/Assets
18.85% 11.05% 43.94% 35.59% 98.23% 0.85% 0.99% 0.00% 0.00% 0.00%
Debt/Equity
(0.06) (0.03) (0.06) (0.04) (3.21) 0.01 0.01 0.00 0.00 0.00
Asset Turnover
0.02 0.05 0.08 0.10 0.03 0.00 0.01 0.01 0.03 0.04
Operating CF/Net income
0.58 0.41 0.41 0.47 0.17 0.08 0.32 0.62 0.92 0.76
Capex/Depreciation
(0.24) 0.00 (0.01) (0.01) 0.00 (0.03) (3.65) (1.03) (0.56) (0.55)
Interest Coverage
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE
193.88% 159.58% 161.75% 136.79% 159.81% (437.56%) (98.91%) (80.73%) (97.03%) (321.48%)
ROA
(480.19%) (565.79%) (848.38%) (1,101.88%) (387.82%) (330.62%) (95.12%) (71.73%) (72.15%) (174.11%)
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% (2,159.78%) (952.51%) 0.00% 0.00% 0.00%
Return on Tangible Assets
164.10% 125.83% 140.67% 107.84% (520.90%) (209.55%) (123.72%) (113.99%) (115.73%) 6,268.49%
Average Days of Receivables
60.16 171.23 95.36 89.85 80.58 39.67 48.75 48.32 171.49 15.73
Research and Development Expense of Revenue
7,921.98% 2,657.28% 1,363.24% 1,324.85% 1,138.70% 1,585.00% 2,932.72% 2,767.22% 1,672.54% 2,806.42%
Selling, General and Administrative Expense of Revenue
13,565.38% 7,781.36% 5,626.58% 5,261.31% 2,535.32% 55,706.09% 13,005.43% 7,772.29% 1,302.04% 1,637.00%
Intangible Assets out of Total Assets
0.61 0.51 0.68 0.50 0.15 0.03 0.05 0.06 0.05 0.13
Share Based Compensation of Revenue
6,969.23% 4,445.43% 2,161.62% 1,275.77% 898.31% 50,236.96% 10,528.30% 5,338.13% 701.40% 924.55%
Graham Net Nets
(4.78) (5.46) (26.81) (2,362.27) (4.58) 79.95 29.52 24.21 13.32 (1.10)
Graham Number
397,818.40 424,836.70 459,643.82 203,856.21 932.01 0.00 0.00 0.00 0.00 0.00
Earnings Yield
(1,034.31%) (792.79%) (3,018.52%) (216,849.45%) (2,069.55%) (17,754.23%) (3,757.35%) (2,937.11%) (1,622.38%) (2,694.92%)
Free Cash Flow Yield
(381.73%) (267.32%) (1,422.53%) (115,905.00%) (367.82%) (1,317.40%) (1,494.43%) (2,143.69%) (1,726.00%) (2,276.49%)
Revenue per Share
364.00 810.00 1,110.00 433.33 3.91 0.77 0.66 0.69 1.03 0.80
Operating CF per Share
(50,027.00) (38,538.00) (51,046.00) (23,062.33) (99.71) (56.06) (32.69) (30.49) (21.20) (23.99)
Capex per Share
(1,888.00) (36.00) (129.00) (118.67) 0.00 (0.52) (2.43) (0.81) (0.27) (0.26)
Free Cash Flow per Share
(51,915.00) (38,574.00) (51,175.00) (23,181.00) (99.71) (56.58) (35.12) (31.30) (21.47) (24.25)
Cash per Share
318.00 4,517.00 1,175.00 5.67 155.56 353.98 81.53 52.47 27.65 6.57
Shareholders Equity per Share
(50,003.00) (68,366.00) (86,410.00) (42,587.33) (67.59) 363.59 87.52 47.44 21.98 0.79
Interest Debt per Share
0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
(50,003.00) (68,366.00) (86,410.00) (42,587.33) (67.59) 363.59 87.52 47.44 21.98 0.79
Free Cash Flow
(5.19) (3.86) (5.12) (6.95) (1.96) (3.36) (6.35) (6.60) (8.34) (10.91)
Working Capital
(5.77) (7.83) (9.07) (13.65) 2.14 21.10 14.69 8.78 7.40 (0.59)
Capital Expenditures
(0.19) 0.00 (0.01) (0.04) — (0.03) (0.44) (0.17) (0.11) (0.12)
Net Current Asset Value
(6.51) (8.08) (9.65) (14.17) (2.49) 20.61 14.53 8.78 7.40 (0.59)
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.78 0.74 0.70 0.88 0.15
Capex to Sales
5.19 0.04 0.12 0.27 0.00 0.67 3.67 1.17 0.26 0.32
Net Profit Margin
(23,726.10%) (11,660.12%) (11,277.30%) (11,267.62%) (14,639.87%) (96,311.52%) (15,438.06%) (7,145.20%) (2,239.25%) (3,959.41%)
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
1.57 2.68 14.44 56.85 63.90 32.17 0.46 0.47 0.52 0.59
Cash ROIC
118.00% 67.55% 66.00% 57.03% (33.09%) (7.87%) (20.08%) (32.21%) (44.61%) (336.83%)
Accounts Receivable Turnover
0.73 3.68 3.31 4.26 3.14 4.18 11.41 8.26 3.86 3.53
Accounts Payable Turnover
0.00 0.11 0.00 0.00 0.00 2.42 2.53 0.00 0.08 0.03
Inventory Turnover
0.00 0.00 — — — 0.00 0.00 — 0.00 0.00
Average Days of Payables
8,336,600.00 3,455.61 0.00 0.00 0.00 90.36 222.22 0.00 6,275.14 20,573.42
Days of Inventory on Hand
0.00 0.00 — — — 0.00 0.00 — 0.00 0.00
Average Receivables
0.05 0.02 0.03 0.03 0.02 0.01 0.01 0.02 0.10 0.10
Average Payables
2.42 2.37 2.17 1.92 1.04 0.08 0.11 0.18 0.34 0.91
Average Assets
1.80 1.67 1.48 1.33 2.91 13.40 19.44 14.52 12.45 8.18
Average Common Equity
(4.45) (5.92) (7.74) (10.71) (7.05) 10.13 18.70 12.90 9.25 4.43

Fold the line items

Columns are period end dates